4D Molecular Therapeutics (FDMT) EBT Margin (2020 - 2026)
4D Molecular Therapeutics (FDMT) reported EBT Margin of 2256.51% for Q1 2026, up 34087920.0% year-over-year from N/an in Q1 2025, and down 9987.58% quarter-over-quarter from 22.82% in Q4 2025.
4D Molecular Therapeutics (FDMT) EBT Margin (2020 - 2026) Analysis & Trends
4D Molecular Therapeutics (FDMT) has 7 years of EBT Margin data on file, last reported at 2256.51% in Q1 2026.
- EBT Margin for Q1 2026 came in at 2256.51%, up 34087920.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 182.21% (up 76694387.0% YoY), and the FY2025 annual result was 164.39%, up 43440588.0% from the prior year.
- EBT Margin fell to 2256.51% in Q1 2026 per FDMT's latest filing, from 22.82% in the prior quarter.
- Over five years, EBT Margin peaked at 169852.63% in Q4 2023 and troughed at 4965000.0% in Q4 2024.
- A 5-year average of 464223.78% and a median of 12394.98% in 2023 frame the typical range for EBT Margin.
- The sharpest annual moves came in 2024 and 2025: EBT Margin slumped 513485263 bps in 2024, then surged 496502282 bps in 2025.
- A 5-year view of EBT Margin shows it stood at 2195.83% in 2022, then jumped by 7835 bps to 169852.63% in 2023, then slumped by 3023 bps to 4965000.0% in 2024, then soared by 100 bps to 22.82% in 2025, then tumbled by 9988 bps to 2256.51% in 2026.
- Business Quant data shows FDMT's EBT Margin at 2256.51% in Q1 2026, 22.82% in Q4 2025, and 63172.22% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 6.40% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 41.95% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | 4D Molecular Therapeutics | 656.48 Mn | 656.48 Mn | - | -2,256.51% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2,256.51% |
| Dec 31, 2025 | 22.82% |
| Sep 30, 2025 | -63,172.22% |
| Jun 30, 2025 | -363,980.00% |
| Mar 31, 2025 | -343,135.71% |
| Dec 31, 2024 | -4,965,000.00% |
| Sep 30, 2024 | -1,461,400.00% |
| Jun 30, 2024 | -698,160.00% |
| Mar 31, 2024 | -115,682.14% |
| Dec 31, 2023 | 169,852.63% |
| Sep 30, 2023 | -49.98% |
| Jun 30, 2023 | -12,394.98% |
| Mar 31, 2023 | -9,618.46% |
| Dec 31, 2022 | -2,195.83% |
| Sep 30, 2022 | -5,140.00% |
| Jun 30, 2022 | -17,337.04% |
| Mar 31, 2022 | -2,156.85% |
| Dec 31, 2021 | -27,256.52% |
| Sep 30, 2021 | -1,627.09% |
| Jun 30, 2021 | -52.05% |